ASCO 2020: New optimised precision radiotherapy can reduce swallowing difficulties for head and neck cancer patients 30 May 2020 A new optimised intensity-modulated radiation therapy (IMRT) could spare head and neck cancer patients’ adverse life-long side effects after treatment, new clinical trial results have shown. Find out more Show/Hide
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020 The ICR has criticised the decision by NICE not to recommend the immunotherapy, pembrolizumab, as a first-line treatment for patients with advanced head and neck cancer and is calling for an urgent reassessment of the evidence for the drug’s benefit. Find out more Show/Hide
Major trial backs immunotherapy as standard first-line treatment for head and neck cancer 23 Nov 2019 Immunotherapy is better than standard ‘extreme’ chemotherapy as first-line treatment for advanced head and neck cancer and can keep some patients alive for more than three years, a major new trial reports. Find out more Show/Hide
ASCO 2019: Immunotherapy better than aggressive chemotherapy as first treatment option for recurrent head and neck cancer 04 Jun 2019
ESMO 2018: Immunotherapy effective as first-line treatment for advanced head and neck cancer 22 Oct 2018
Breakthrough for advanced head and neck cancer patients as nivolumab made available on the Cancer Drugs Fund 13 Oct 2017